2018
DOI: 10.1182/blood-2018-99-110555
|View full text |Cite
|
Sign up to set email alerts
|

LYMRIT 37-01: A Phase I/II Study of 177lu-Lilotomab Satetraxetan (Betalutin®) Antibody-Radionuclide-Conjugate (ARC) for the Treatment of Relapsed Non-Hodgkin's Lymphoma (NHL) — Analysis with 6-Month Follow-up

Abstract: Introduction: Most indolent NHL patients (pts) have advanced stage disease at diagnosis, and no curative therapy exists. The mainstay of both first- and second-line (2L) therapy is anti-CD20 chemo-immunotherapy, and although initially effective, most pts relapse, with median PFS decreasing markedly after 2L and 3rd-line therapies. In addition, many pts eventually develop resistance to rituximab (RTX)/RTX-containing regimens, thus therapeutic targets other than CD20 are important. Those who develop resistance t… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
8
0
2

Year Published

2019
2019
2021
2021

Publication Types

Select...
5
2

Relationship

2
5

Authors

Journals

citations
Cited by 9 publications
(10 citation statements)
references
References 0 publications
0
8
0
2
Order By: Relevance
“…There was high rates of treatment-related AEs, particularly hematotoxicities, and this needs to be considered for future clinical development programs targeting CD37. However, recent promising results from a phase I/II study of 177 Lu-lilotomab satetraxetan, an anti-CD37 antibody-radionuclide conjugate, in which 65% of patients with FL responded, including CR in 24% of patients, also confirm the value of targeting CD37 [ 22 ]. As with our study, the incidence of Grade 3/4 neutropenia (53%) was high; grade 3/4 thrombocytopenia was also common (48%).…”
Section: Discussionmentioning
confidence: 99%
“…There was high rates of treatment-related AEs, particularly hematotoxicities, and this needs to be considered for future clinical development programs targeting CD37. However, recent promising results from a phase I/II study of 177 Lu-lilotomab satetraxetan, an anti-CD37 antibody-radionuclide conjugate, in which 65% of patients with FL responded, including CR in 24% of patients, also confirm the value of targeting CD37 [ 22 ]. As with our study, the incidence of Grade 3/4 neutropenia (53%) was high; grade 3/4 thrombocytopenia was also common (48%).…”
Section: Discussionmentioning
confidence: 99%
“…There are currently three CD37 targeting therapies in clinical development [10][11][12][13]. One of these compounds, 177 Lu-lilotomab satetraxetan (Betalutin1), applies the β-emitter lutetium-177 as the cytotoxic payload, and is currently in clinical phase 2b for patients with relapsed follicular lymphoma (NCT01796171) [13]. Unlike NHL, where enlarged lymph nodes and tumours dominate the clinical picture, CLL more often presents as a disseminated leukemic disease.…”
Section: Introductionmentioning
confidence: 99%
“…Die Tumordosen waren in der Phase I-Studie relativ niedrig und lagen bei weniger als 1 Gy [30]. Dennoch war die Kombination aus nicht radioaktivem Lilotomab und 177 Lu-Lilotomab in der Lymrit-37-01-Studie [32] effektiv für die Behandlung von rezidivierten indolenten Non-Hodgkin-Lymphomen (NHL). Dies ist wahrscheinlich auf die hohe Strahlenempfindlichkeit von Lymphomen und immunologische Effekte des nicht radioaktiven Lilotomab zurückzuführen.…”
Section: Cd37/lilotomabunclassified
“…In der Lymrit-37-01 Phase I-Studie [32] "Lipid rafts"/CLR1404 "Lipid rafts" ("Lipidflöße") sind Bereiche in Zellmembranen mit einem hohen Gehalt an Sphingomyelinen, Glycosphingolipiden und Cholesterin [33]. Lipid rafts bilden ein Kompartiment für Wachstumsfaktoren und die von diesen Rezeptoren vermittelten Signale [34].…”
Section: Cd37/lilotomabunclassified